Military acute concussion evaluation

BRAINBox Solutions, USA Hockey Enter Collaboration to Evaluate Potential of Biomarkers for Concussion Diagnosis and Prognosis in Student Athletes

Retrieved on: 
Thursday, February 9, 2023
Biomarker, Hockey, Brainbox, Blood, Concussion, DC, Diagnosis, TBI, Military acute concussion evaluation, Bangladesh Technical Education Board, City of Hope National Medical Center, Saliva, Children's National Hospital, ATE, Athlete, Patient, Clinical trial, Coronavirus Scientific Advisory Board, Research, Sport, Risk, Student, Associate, Emergency medicine, USA Hockey, MD, Pharmaceutical industry

Dr. Stuart's research project, funded by the USA Hockey Foundation, will be utilizing BRAINbox Solutions' patented, proprietary protected biomarkers in blood and saliva as part of his study.

Key Points: 
  • Dr. Stuart's research project, funded by the USA Hockey Foundation, will be utilizing BRAINbox Solutions' patented, proprietary protected biomarkers in blood and saliva as part of his study.
  • The research is designed to better understand the impact of subclinical head trauma and acute concussion in high endurance contact sport athletes.
  • This data will also inform BRAINBox's planned clinical trial of its multi-modal concussion diagnostic and prognostic test, BRAINBox TBI, in sports and this age group.
  • "We seek to advance our understanding of concussion and improve prevention, diagnosis and management of this common condition."

Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company

Retrieved on: 
Tuesday, September 27, 2022
Central nervous system, Fatty liver disease, Multiple sclerosis, Traumatic brain injury, Chronic kidney disease, FDA, Military acute concussion evaluation, Compound annual growth rate, NASH, Statista, PAD, OTCQB, Company, CMS, Contract, Wound healing, Growth, Post-concussion syndrome, Liver disease, Acquisition, Private Securities Litigation Reform Act, Therapy, Build Up, U.S. Securities and Exchange Commission, Securities & Exchange Commission of Pakistan, CE, Pain, TBI, Cardiovascular disease, Stroke, Risk factor, Edema, Agreement, CNS, Board, Security (finance), Corporate development, GLOBE, CAGR, Renewable energy

Los Angeles, CA., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) and Western Star Concrete LLC, a highly profitable Texas concrete construction company located in the greater Dallas region, today announced the signing of a definitive purchase agreement for Endonovo to acquire all of Western Stars assets and business operations.

Key Points: 
  • Los Angeles, CA., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) and Western Star Concrete LLC, a highly profitable Texas concrete construction company located in the greater Dallas region, today announced the signing of a definitive purchase agreement for Endonovo to acquire all of Western Stars assets and business operations.
  • The current profitability and future demonstrable growth provides a great value for Endonovo and our shareholders, CEO Alan Collier said in making the announcement.
  • Western Star financial performance has sustained a 15% to 20% CAGR over a three-year financial lookback in the specialized concrete construction sector.
  • Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals therapeutic devices for pain relief, general wellness and wound curatives.

Endonovo Therapeutics Releases Comparative Analysis Demonstrating

Retrieved on: 
Thursday, July 28, 2022
CA, DEVICE, Swelling, TIME, Multiple sclerosis, GLOBE, Traumatic brain injury, U.S. Securities and Exchange Commission, Risk factor, Liver disease, PAD, Edema, Cardiovascular disease, Post-concussion syndrome, Private Securities Litigation Reform Act, CMS, NASH, Chronic kidney disease, CNS, Therapy, Fatty liver disease, Stroke, Hertz, News, CE, Central nervous system, FOR, Military acute concussion evaluation, FDA, Company, Security (finance), Patient, OTCQB, TBI, Pain, Comparison, PEAK, PEMF, Wound healing, Medical imaging, Pharmaceutical industry, Medical device

Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®.

Key Points: 
  • Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse medical device for post-operative pain relief compared with Bioelectronics Corporations RecoveryRx.
  • Comparison of SofPulse to RecoveryRx in technical characteristics demonstrated superiority of the design, efficacy and health benefits of the Endonovo SofPulse medical device.
  • Although both SofPulse and RecoveryRx are PEMF devices, there is little comparison in market, efficacy or effectiveness between the two.
  • Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals therapeutic devices for pain relief, general wellness and wound curatives.

Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management

Retrieved on: 
Thursday, July 21, 2022
Swelling, Multiple sclerosis, Injection, Traumatic brain injury, U.S. Securities and Exchange Commission, Â, Use, Risk factor, Liver disease, PAD, Edema, Post-concussion syndrome, Cardiovascular disease, Private Securities Litigation Reform Act, CMS, NASH, Chronic kidney disease, CNS, Therapy, Fatty liver disease, Stroke, Hertz, Narcotic, Catheter, News, CE, Inflammation, Central nervous system, Military acute concussion evaluation, FDA, Company, Security (finance), Patient, TBI, Pain, Wound healing, Birth control, Dentistry, Medical imaging

SofPulse may provide significant cost-savings per procedure compared to other post-operative pain solution options.

Key Points: 
  • SofPulse may provide significant cost-savings per procedure compared to other post-operative pain solution options.
  • SofPulse offers a superior non-invasive alternative/non-pharmacologic treatment for post-procedural pain and edema.
  • For full resource to the 17 related scientific references regarding claims in this news release, contact Endonovos Investor Relations.
  • Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals therapeutic devices for pain relief, general wellness and wound curatives.

Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company

Retrieved on: 
Thursday, June 9, 2022
Hertz, CA, Tax, OTCQB, Company, Stroke, Liver disease, EBITDA, Risk factor, IP, Central nervous system, NASH, Edema, Military acute concussion evaluation, Security (finance), CE, U.S. Securities and Exchange Commission, Confidentiality, Pain, Post-concussion syndrome, Â, Traumatic brain injury, Construction, Chronic kidney disease, Therapy, FDA, Growth, Letter, Cardiovascular disease, GLOBE, Interest, Private Securities Litigation Reform Act, Target, Acquisition, GAAP, Depreciation, LOI, CMS, Multiple sclerosis, Intention, PAD, CNS, Fatty liver disease, TBI, CAGR, Wound healing, Risk management

Since 2018, growth for the target company has gone from $9.5 Million in revenue to over $47 Million in 2021 for an average CAGR of 106%.

Key Points: 
  • Since 2018, growth for the target company has gone from $9.5 Million in revenue to over $47 Million in 2021 for an average CAGR of 106%.
  • Once completed, the Target and is expected to significantly increase performance of Endonovo as a holding company and supplement financial results from its traditional product line of medical devices for post-operative pain treatment.
  • We expect that the completion of the LOI to acquire the highly profitable and market leading target company will establish Endonovos standing as a successful holding company by delivering long-term fundamental shareholder value for investors, Collier said.
  • Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals therapeutic devices for pain relief, general wellness and wound curatives.

Endonovo Therapeutics Inc. (ENDV) Appoints Garry Michael Kann As Head of Corporate Development To Identify And Acquire Profitable Companies For Endonovo

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Central nervous system, Mergers and acquisitions, Fatty liver disease, Wound healing, Head, Time, Pain, Hertz, Security (finance), Lead, Kean University, PAD, Therapy, Industry, Chronic kidney disease, Company, Corporation, Private Securities Litigation Reform Act, CA, Edema, Risk factor, Multiple sclerosis, U.S. Securities and Exchange Commission, Traumatic brain injury, Review, Targets, Acquisition, Corporate development, Liver disease, Military acute concussion evaluation, TBI, FDA, Construction, NASH, Stroke, Cardiovascular disease, CMS, Post-concussion syndrome, CNS, CE, SEC, Financial services, Risk management

By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company.

Key Points: 
  • By Endonovo, establishing a Mergers and Acquisition division run by Mr. Kann, Endonovo will become a diversified holding company.
  • During that time, he has completed more than 60 merger & acquisition (M&A) transactions exceeding $2 billion in value.
  • We look to acquire companies which will be immediately accretive to Endonovos top line revenue and bottom line profits to maximize shareholder value.
  • Alan Collier, Endonovos CEO, states Garry Michael Kann has been a long-time leading voice in the merger and acquisitions community.

Endonovo Therapeutics Inc. (ENDV) Announces it has filed a Regulation A+ Financing & Retained Dalmore Group to Provide Operations & Compliance

Retrieved on: 
Wednesday, February 16, 2022
Emerald, Wound healing, CNS, TBI, Traumatic brain injury, CMS, Company, Legion, WINC, Stroke, SEC, Hertz, PR, U.S. Securities and Exchange Commission, Solution, Reg, CA, Private Securities Litigation Reform Act, Security (finance), OTC, GLOBE, Pain, PAD, NASH, Military acute concussion evaluation, 123 Reg, Aptera Motors, Cardiovascular disease, Therapy, FDA, Note, Post-concussion syndrome, Marketing, Acquisition, Central nervous system, Edema, Growth, Research, Risk factor, Multiple sclerosis, CE, Chronic kidney disease, Industry, United States securities regulation, Financial adviser, Dalmore

In retaining Dalmore Group, Endonovo has positioned their Reg A+ Financing to capitalize on the strengths and successes that Dalmore Group has established as being an industry leading broker-dealer in Reg A+ Financing services.

Key Points: 
  • In retaining Dalmore Group, Endonovo has positioned their Reg A+ Financing to capitalize on the strengths and successes that Dalmore Group has established as being an industry leading broker-dealer in Reg A+ Financing services.
  • As a consultant Dalmore Group offers Endonovo marketing guidance and experienced securities regulation compliance review as well as a wide variety of financial funding alternatives and structures.
  • Dalmore clients include a mix of private and publicly listed companies in both the US and Canada.
  • Completing our Reg A+ offerings with Dalmore Group is, in our opinion, the best option available to us.